Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L-type amino acid transporter (LAT) family comprises several members (LAT1-LAT4) that mediate the sodium-independent transport of large neutral amino acids. LAT1 (SLC7A5) is the most well-studied member and forms a heterodimeric complex with 4F2hc/CD98. It is highly expressed at the blood-brain barrier, placenta, and in various cancers, playing a crucial role in supplying essential amino acids for cell growth and proliferation. It has clinical significance because its overexpression in tumors makes it a therapeutic target, and its presence at the BBB allows it to be exploited for drug delivery to the brain.
Targeted inhibition of amino acid transport
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-type Amino Acid Transporter (LAT).